Clinical trial participant engagement that holds up for long-acting regimens

Tell us about your project

Please reach out to us about your project and see how we can help you accomplish your goals.

We value your privacy and will never share your contact information

Please note that submissions without a valid business email address or business phone number may not receive a timely response

Healthcare Solutions

If you're in healthcare, you owe it to yourself to learn how you can make your everyday business processes more efficient and save money at the same time. We can help in automating many of your routine and repetitive tasks, including Patient Engagement surveys.

Contact us to learn more

Transportation Solutions

If you're in the transportation business, you can automate many of your routine tasks like package notifications, surveys, collection calls and more. Improve your customer satisfaction by extending your service hours without extending your costs.

Connect with us to learn more

Per-person timelines, safety screening, and patient-reported outcomes for long-acting injectable trials

Clinical trial participant engagement is the operational spine of any study where each enrollee follows a unique schedule. Long-acting injectable (LAI) regimens – a growing focus in tuberculosis and other fields – move adherence work from daily self-administration to the health system that delivers periodic injections. Recent World Health Organization (WHO) target regimen profiles for LAIs are a reminder that sponsors and sites will need tighter, per-person workflows for scheduling, safety screening, and follow-up.

The practical problem is straightforward: a missed dose or an untriaged symptom has a different cost when each injection is a rare, clinic-based event. Trials and early rollouts that treat participant outreach as a batch email or a single reminder risk losing visits, missing adverse-event signals, and introducing bias when certain groups consistently fail to respond.

Where the schedule quietly breaks

Long-acting regimens often constrain dosing to a small number of encounters. That makes each scheduled visit high-stakes. The usual enrollment pattern – rolling arrivals, varied travel constraints, and differing caregiver support – means every participant has an individual clock. Problems show up where systems assume everyone shares the same calendar.

Scheduling windows that cannot be adjusted around a participant’s availability cause missed dosing encounters. Confirmation and documentation gaps appear when a participant arrives but the site lacks a quick way to record dosing or exceptions. Late symptom reports slip through because outreach was too infrequent or offered only on a single channel. The cost is not just a rescheduled appointment. It is wasted site capacity, protocol deviations that attract monitor attention, and participant frustration that increases dropout risk. Measuring completion by calendar date hides these individual failures; the right metric is an enrollment-relative, per-person completion rate.

What data capture and safety screening actually require

Patient-reported outcome (PRO) collection and safety screening in LAI trials cannot be an afterthought. Sponsors need short, frequent check-ins that feed into an auditable record and surface urgent items to a clinical team. The system must separate routine adherence confirmations from answers that demand immediate attention – and then deliver those alerts through a channel the site trusts.

Channel choice matters for inclusion. Voice-first outreach reaches participants who do not use apps or who prefer a phone call; SMS and secure messaging reach people who can reply on their own schedule. Multilingual delivery and translated verbatim comments keep teams from systematically missing signals from non-English speakers. For programs that expect to collect symptom severity, medication tolerability, or missed-dose reasons, plan for structured answers that a clinician can read quickly rather than long free-text notes.

Operationally useful reporting is simple: per-enrollee timelines, the last contact method attempted, completion status for scheduled check-ins, and a flag for anything that crossed a clinical threshold. When those pieces are missing, sites end up re-calling participants by hand and re-entering answers into the clinical record.

How to catch problems before scale-up

The honest answer is that many failures are visible in small pilots. A short, practical pre-roll checklist saves time and avoids protocol deviations later.

  • Run a rolling-enrollment pilot that mirrors the expected cadence and geography, then watch where participants drop out.
  • Measure completion by participant day-0 rather than by calendar date so you see whether week-2 and month-1 checks actually land on time for each person.
  • Test escalation paths with realistic alerts – do nurses get the right message, and does the alert reach the on-call clinician on evenings and weekends?

Also check language coverage and response-mode mix early. If Spanish or other languages are common in your population, offering outreach only in English biases your capture and undercounts adverse events in groups that already face barriers to care. For many sites, the simplest course is to build a mix of voice, SMS, and secure messaging options so participants can use the channel that works for them.

Documentation matters too – not as a product feature list but as an operational requirement. The study team needs an auditable record that shows who was contacted, which check-ins were completed, and how urgent symptoms were escalated. That record is what keeps monitors and regulators from chasing down answers manually.

Design choices that reduce downstream work

A few concrete design choices shrink the most expensive problems. First, favor branching flows that keep each individual interaction short – participants only receive the questions relevant to their recent responses. Second, separate routine adherence confirmations from safety screens so triage teams see the urgent items first. Third, capture language preference and caregiver permissions at intake so follow-up happens in the right mode from day one.

These are not theoretical. Sponsors who build workflows around per-person timelines and measured channel mixes avoid the last-minute scramble when an entire cohort needs dose reminders in the same week. The same approaches also support equitable access: phone-first options and translated outreach routinely bring in participants who web-only recruitment misses.

The WHO target regimen profiles ask product developers to think about dosing frequency, cold-chain requirements, and where injections can be given. Sponsors and sites should ask parallel operational questions about engagement and safety monitoring now, because the communication model you choose determines whether a LAI trial can scale without breaking site budgets or participant trust.

Related coverage: Target regimen profiles for long-acting injectables for tuberculosis prevention and treatment – World Health Organization